Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells

BACKGROUND: Advanced or metastatic prostate cancer (PCa) is still an incurable malignancy with high lethality and a poor prognosis. Despite the remarkable success of immunotherapy against many types of cancer, most patients with PCa receive minimal benefit from current immunotherapeutic strategies,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sheng, Huang, Maohua, Chen, Minfeng, Sun, Zhiting, Jiao, Yubo, Ye, Geni, Pan, Jinghua, Ye, Wencai, Zhao, Jianfu, Zhang, Dongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277537/
https://www.ncbi.nlm.nih.gov/pubmed/37295817
http://dx.doi.org/10.1136/jitc-2022-006381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277537/
https://www.ncbi.nlm.nih.gov/pubmed/37295817
http://dx.doi.org/10.1136/jitc-2022-006381

Ejemplares similares